Secondary Budd–Chiari syndrome caused by adult T‐cell leukemia/lymphoma
Pathology International · 2023
DOI: 10.1111/pin.13358 ↗Kurz gefasst
Leserbrief in der Zeitschrift Pathology International, 2023. Verfasst von Ryutaro Tominaga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Budd-Chiari Syndrome, Leukemia-Lymphoma, Adult T-Cell, Lymphoma. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pathology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
- Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
ORCID-Profile: Ryutaro Tominaga, Naota Okabe, Hisashi Oshiro
Zitieren
APA
Tominaga, R., Yoshimura, K., Kawamura, M., Kako, S., Kanda, Y., Morikawa, H., Ando, S., Okabe, N., Hiruta, M., Tanaka, A., & Oshiro, H. (2023). Secondary Budd–Chiari syndrome caused by adult T‐cell leukemia/lymphoma. Pathology International. https://doi.org/10.1111/pin.13358
Vancouver
Tominaga R, Yoshimura K, Kawamura M, Kako S, Kanda Y, Morikawa H, et al. Secondary Budd–Chiari syndrome caused by adult T‐cell leukemia/lymphoma. Pathology International. 2023. doi:10.1111/pin.13358
BibTeX
@article{Tominaga2023,
author = {Tominaga, Ryutaro and Yoshimura, Kazuki and Kawamura, Masakatsu and Kako, Shinichi and Kanda, Yoshinobu and Morikawa, Haruka and Ando, Shiori and Okabe, Naota and Hiruta, Masahiro and Tanaka, Akira and Oshiro, Hisashi},
title = {Secondary Budd–Chiari syndrome caused by adult T‐cell leukemia/lymphoma},
journal = {Pathology International},
year = {2023},
doi = {10.1111/pin.13358}
}
EUVIMED